Overview
- Editors:
-
-
Massimo Filippi
-
Neuroimaging Research Unit Department of Neuroscience, Scientific Institute and University Ospedale San Raffaele, Milan, Italy
-
Giancarlo Comi
-
Clinical Trials Unit Department of Neuroscience, Scientific Institute and University Ospedale San Raffaele, Milan, Italy
- The book represents an updated report of the most recent advances in primary progressive multiple sclerosis
Access this book
Other ways to access
Table of contents (11 chapters)
-
-
- M. Filippi, M. Rovaris, G. Comi
Pages 1-3
-
- G. Rice, M. Kremenchutzky, D. Cottrell, J. Baskerville, G. Ebers
Pages 5-10
-
-
-
-
-
- J. S. Wolinsky, P. A. Narayana, R. He
Pages 47-61
-
- G. T. Ingle, A. J. Thompson, D. H. Miller
Pages 63-76
-
- M. Rovaris, G. Comi, M. Filippi
Pages 77-88
-
- Z. Caramanos, A. C. Santos, S. J. Francis, S. Narayanan, D. Pelletier, D. L. Arnold
Pages 89-112
-
-
Back Matter
Pages 125-128
About this book
"Why are there no effective treatments for my condition? Why do researchers exclude patients with primary progressive multiple sclerosis from enrolling in clinical trials? Please let me know if you hear of studies that I might be allowed to enter or treatments that I could try for my condition. " Thus, in recent years, the sad lament of the patient with primary progressive MS (PPMS). This variant, often in the guise of a chronic progressive myelopathy or, less commonly, progressive cerebellar or bulbar dysfunction, usually responds poorly to corticosteroids and rarely seems to benefit to a significant degree from intensive immunosuppressive treatments. In recent years, most randomized clin ical trials have excluded PPMS patients on two counts. Clinical worsening devel ops slowly in PPMS and may not be recognized during the course of a 2-or 3-year trial even in untreated control patients. This factor alone adds to the potential for a type 2 error or, at the very least, inflates the sample size and duration of the trial. In addition, there is mounting evidence that progressive axonal degeneration and neuronal loss (rather than active, recurrent inflammation) may be important components of the pathology in this form of the disease. Although contemporary trials are evaluating whether PPMS patients may benefit from treatment with the ~-interferons and glatiramer acetate, preliminary, uncontrolled clinical experi ence suggests that the results may not be dramatic.
Editors and Affiliations
-
Neuroimaging Research Unit Department of Neuroscience, Scientific Institute and University Ospedale San Raffaele, Milan, Italy
Massimo Filippi
-
Clinical Trials Unit Department of Neuroscience, Scientific Institute and University Ospedale San Raffaele, Milan, Italy
Giancarlo Comi
